Contraindications to menotropin (hMG)
Menotropin — human menopausal gonadotrophin, or hMG — is a prescription fertility medicine that supplies the hormones FSH and LH to stimulate the ovaries or testes. It is a powerful hormonal treatment used in assisted reproduction and in certain cases of infertility, and like any potent drug it has clear situations in which it must not be used. The editorial team sets out the recognised contraindications to menotropin and the reasons behind them, strictly as background information.
What menotropin is and how it is used
Menotropin is a purified preparation of gonadotrophins extracted historically from the urine of postmenopausal women, containing follicle-stimulating hormone (FSH) and luteinising hormone (LH) activity. These are the same pituitary hormones that normally drive the ovaries and testes, so administering them externally stimulates the gonads directly.
In women, its main use is controlled ovarian stimulation — encouraging the ovaries to develop follicles during fertility treatment such as IVF, or inducing ovulation in certain forms of infertility. In men, gonadotrophin therapy can stimulate sperm production in specific types of hypogonadism, generally alongside other hormones and under specialist care.
Because the drug activates the reproductive system so strongly, it is always prescribed and monitored by fertility or endocrine specialists, usually with ultrasound and blood tests to track the response. The dosing and schedule are individualised and are well outside the scope of a general article.
This potency is exactly why contraindications matter. A medicine that reliably stimulates the ovaries can cause serious harm in the wrong patient, and recognising those situations in advance is central to safe practice.
Absolute contraindications
Some conditions make menotropin unsuitable outright. These absolute contraindications appear in official product information and reflect situations where stimulating the reproductive axis is clearly dangerous or futile.
| Contraindication | Reason |
|---|---|
| Known hypersensitivity to the preparation | Risk of allergic reaction |
| Hormone-sensitive tumours of breast, ovary, uterus (women) or prostate (men) | Gonadotrophins/oestrogen may stimulate growth |
| Tumours of the pituitary or hypothalamus | Underlying cause must be addressed first |
| Undiagnosed abnormal vaginal bleeding | Cause must be established before stimulation |
| Ovarian enlargement or cyst not due to polycystic ovary syndrome | Risk of further enlargement or rupture |
| Primary ovarian or testicular failure | Gonads cannot respond; treatment ineffective |
| Pregnancy and breastfeeding | No indication; potential harm |
The thread running through this list is twofold. First, any hormone-sensitive cancer is a clear bar, because the medicine can fuel growth. Second, treatment is pointless and potentially harmful where the gonads themselves have failed, since there is nothing left to stimulate — the problem lies in the organ, not the signal.
Undiagnosed bleeding and unexplained ovarian masses must be investigated before any stimulation, because hormonal treatment could worsen or mask a serious underlying condition. These are not cautions to weigh but lines not to cross.
Specialists confirm the absence of these conditions as part of the standard work-up before fertility treatment, which is one reason the drug is never appropriate for self-use.
Relative contraindications and cautions
Beyond the absolute bars, several situations call for particular caution and careful risk assessment. Here treatment may still proceed, but only with heightened monitoring and clear justification.
- Polycystic ovary syndrome (PCOS): the ovaries can over-respond, raising the risk of ovarian hyperstimulation syndrome and multiple pregnancy.
- Thrombophilia or history of blood clots: ovarian stimulation and the resulting high oestrogen levels increase clotting risk.
- Previous abdominal or pelvic surgery: may alter the response or complicate monitoring.
- Uncontrolled thyroid or adrenal disease: should be stabilised first, as these affect fertility and safety.
In each of these, the specialist weighs the benefit of treatment against the specific hazard and adjusts dose, monitoring intensity and the threshold for cancelling a cycle. The judgement is individual and depends on information — scans, bloods, history — that only a clinic can gather.
The recurring theme is that menotropin's effect is strong and somewhat unpredictable between individuals. A dose that produces a modest response in one woman can cause dramatic over-stimulation in another, which is why cautions exist even where treatment is not forbidden outright.
This variability also explains why monitoring is not optional. Without ultrasound and hormone measurements to see how the ovaries are responding, there is no safe way to steer the treatment.
The central risk: ovarian hyperstimulation
The most important hazard that underlies many of the contraindications is ovarian hyperstimulation syndrome (OHSS). This occurs when the ovaries respond too vigorously, becoming enlarged and leaking fluid into the abdomen. Mild cases cause bloating and discomfort; severe cases can cause large fluid shifts, blood concentration, clotting and, rarely, life-threatening complications.
Women with PCOS, those who are young and lean, and those with a high follicle count are especially prone to OHSS, which is why these features prompt extra caution. Clinics mitigate the risk by choosing conservative starting doses, monitoring closely, and sometimes cancelling or modifying a cycle if the response is excessive.
A second major risk is multiple pregnancy. Stimulating several follicles raises the chance of twins or higher-order pregnancies, which carry greater risks for mother and babies. Managing this is part of why careful monitoring and sometimes dose reduction are built into treatment.
These risks make clear why the contraindications are drawn where they are. They are not bureaucratic cautions but reflections of a medicine that can push a delicate biological system too hard.
Why this is strictly a supervised treatment
Everything about menotropin points to one conclusion: it belongs entirely within specialist fertility and endocrine care. The need to exclude hormone-sensitive cancers, to investigate unexplained bleeding, to monitor the ovarian response in real time, and to manage the risks of OHSS and multiple pregnancy all require clinical infrastructure that cannot be improvised.
There is occasional interest in gonadotrophins outside fertility medicine, for instance in the context of restoring the hormonal axis after other interventions. Any such use is a specialist decision, individualised and monitored, and is not something to pursue on one's own. The contraindications described here apply regardless of the reason for use.
For anyone navigating infertility, the practical message is reassuring: the safeguards exist precisely so that this powerful medicine can be used effectively. A thorough pre-treatment assessment is not a hurdle but the mechanism that keeps treatment safe.
Readers exploring this area may also find value in our overviews of how the reproductive hormonal axis works, of the FSH and LH relationship, and of monitoring during fertility treatment, which give broader context.
Conclusions of the editorial team
Menotropin is a potent gonadotrophin therapy whose contraindications follow directly from its biology. It must never be used where hormone-sensitive cancers are present, where the gonads have failed, where bleeding or ovarian masses are unexplained, or in pregnancy.
Relative cautions — PCOS, clotting risk, uncontrolled endocrine disease — call for careful, monitored use. The dominant safety concern throughout is over-stimulation, which can lead to OHSS and multiple pregnancy.
These safeguards are the reason menotropin is strictly a supervised, specialist treatment. The appropriate response to any question about its use is a conversation with a fertility or endocrine clinician, never self-directed treatment.
References
- Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome. Fertil Steril. 2016;106(7):1634-1647.
- National Institute for Health and Care Excellence. Fertility problems: assessment and treatment (CG156). London: NICE.
- The ESHRE Guideline Group on Ovarian Stimulation. Ovarian stimulation for IVF/ICSI: an ESHRE guideline. Hum Reprod Open. 2020;2020(2):hoaa009.
- Lunenfeld B. Historical perspectives in gonadotrophin therapy. Hum Reprod Update. 2004;10(6):453-467.
- Macklon NS, Stouffer RL, Giudice LC, Fauser BC. The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocr Rev. 2006;27(2):170-207.
